CA2911478C - Conjugats destines a la protection contre les composes actifs nephrotiqus - Google Patents
Conjugats destines a la protection contre les composes actifs nephrotiqus Download PDFInfo
- Publication number
- CA2911478C CA2911478C CA2911478A CA2911478A CA2911478C CA 2911478 C CA2911478 C CA 2911478C CA 2911478 A CA2911478 A CA 2911478A CA 2911478 A CA2911478 A CA 2911478A CA 2911478 C CA2911478 C CA 2911478C
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- acid
- kidney
- active compound
- active compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention concerne un conjugué contenant au moins une molécule porteuse sélective pour les reins et au moins une substance active, qui présente une action protectrice pour les reins contre les substances actives néphrotoxiques, un procédé pour fabriquer ces conjugués, leur utilisation pour la protection des reins contre les substances actives néphrotoxiques, et un médicament contenant ledit conjugué.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13002431 | 2013-05-07 | ||
EP13002431.8 | 2013-05-07 | ||
PCT/EP2014/001025 WO2014180533A2 (fr) | 2013-05-07 | 2014-04-16 | Conjugués offrant une protection contre les substances actives néphrotoxiques |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2911478A1 CA2911478A1 (fr) | 2014-11-13 |
CA2911478C true CA2911478C (fr) | 2023-06-13 |
Family
ID=48325357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2911478A Active CA2911478C (fr) | 2013-05-07 | 2014-04-16 | Conjugats destines a la protection contre les composes actifs nephrotiqus |
Country Status (12)
Country | Link |
---|---|
US (2) | US9808535B2 (fr) |
EP (1) | EP2994152B1 (fr) |
JP (1) | JP6510493B2 (fr) |
CN (1) | CN105188729B (fr) |
CA (1) | CA2911478C (fr) |
DK (1) | DK2994152T3 (fr) |
ES (1) | ES2697250T3 (fr) |
HR (1) | HRP20181883T1 (fr) |
HU (1) | HUE039949T2 (fr) |
LT (1) | LT2994152T (fr) |
SI (1) | SI2994152T1 (fr) |
WO (1) | WO2014180533A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2994152B1 (fr) * | 2013-05-07 | 2018-08-15 | Merck Patent GmbH | Conjugués offrant une protection contre les substances actives néphrotoxiques |
US10179095B2 (en) * | 2017-06-07 | 2019-01-15 | Dr. Raymond Laboratories | Autophage activating resveratrol topical composition for skin improvement and treatment |
WO2019014611A2 (fr) * | 2017-07-14 | 2019-01-17 | University Of Massachusetts | Méthodes et compositions de traitement d'inflammation |
CN115298198A (zh) | 2020-01-21 | 2022-11-04 | 上海盟科药业股份有限公司 | 用于肾相关癌症靶向治疗的新型化合物和组合物 |
CN111567725A (zh) * | 2020-04-30 | 2020-08-25 | 江苏师范大学 | 木犀草素作为抑制赭曲霉毒素a肾毒性的食物营养素的应用 |
CN117642419A (zh) * | 2021-07-21 | 2024-03-01 | 上海盟科药业股份有限公司 | 用于肾脏疾病靶向治疗的化合物和组合物 |
WO2024118760A1 (fr) * | 2022-11-29 | 2024-06-06 | Cornell University | Système d'administration de médicament lié à un peptide |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4645661A (en) * | 1984-06-29 | 1987-02-24 | St. Jude Children's Research Hospital | Method for alleviating cisplatin-induced nephrotoxicity and dithiocarbamate compounds for effecting same |
EP0932614A1 (fr) * | 1996-09-09 | 1999-08-04 | Zealand Pharmaceuticals A/S | Promedicaments peptidiques contenant une sequence de liaison alpha-hydroxyacide |
DE10006572A1 (de) * | 2000-02-14 | 2001-08-23 | Deutsches Krebsforsch | Oligonucleotid-Konjugate |
PT1919947E (pt) | 2005-08-26 | 2013-05-22 | Abbvie Inc | Análogos de α-msh terapeuticamente activos |
DE102007004424A1 (de) * | 2007-01-23 | 2008-07-24 | Bayer Schering Pharma Aktiengesellschaft | Eisenoxid-bindende Peptide |
EP2277547A1 (fr) * | 2009-07-20 | 2011-01-26 | Merck Patent GmbH | Conjugué d'epsilon-polylysine et son utilisation |
WO2014180534A1 (fr) * | 2013-05-07 | 2014-11-13 | Merck Patent Gmbh | Peptides et conjugués peptide-principe actif pour ciblage rénal |
EP2994152B1 (fr) * | 2013-05-07 | 2018-08-15 | Merck Patent GmbH | Conjugués offrant une protection contre les substances actives néphrotoxiques |
-
2014
- 2014-04-16 EP EP14718515.1A patent/EP2994152B1/fr active Active
- 2014-04-16 HU HUE14718515A patent/HUE039949T2/hu unknown
- 2014-04-16 JP JP2016512239A patent/JP6510493B2/ja active Active
- 2014-04-16 US US14/889,553 patent/US9808535B2/en active Active
- 2014-04-16 WO PCT/EP2014/001025 patent/WO2014180533A2/fr active Application Filing
- 2014-04-16 CA CA2911478A patent/CA2911478C/fr active Active
- 2014-04-16 LT LTEP14718515.1T patent/LT2994152T/lt unknown
- 2014-04-16 ES ES14718515T patent/ES2697250T3/es active Active
- 2014-04-16 DK DK14718515.1T patent/DK2994152T3/en active
- 2014-04-16 SI SI201430961T patent/SI2994152T1/sl unknown
- 2014-04-16 CN CN201480025948.0A patent/CN105188729B/zh active Active
-
2017
- 2017-10-03 US US15/723,444 patent/US10413614B2/en active Active
-
2018
- 2018-11-12 HR HRP20181883TT patent/HRP20181883T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CN105188729A (zh) | 2015-12-23 |
CA2911478A1 (fr) | 2014-11-13 |
SI2994152T1 (sl) | 2018-12-31 |
DK2994152T3 (en) | 2018-11-26 |
US9808535B2 (en) | 2017-11-07 |
HUE039949T2 (hu) | 2019-02-28 |
EP2994152A2 (fr) | 2016-03-16 |
JP2016523825A (ja) | 2016-08-12 |
ES2697250T3 (es) | 2019-01-22 |
US20160114054A1 (en) | 2016-04-28 |
LT2994152T (lt) | 2018-11-26 |
WO2014180533A2 (fr) | 2014-11-13 |
US10413614B2 (en) | 2019-09-17 |
US20180015173A1 (en) | 2018-01-18 |
JP6510493B2 (ja) | 2019-05-08 |
CN105188729B (zh) | 2021-11-09 |
HRP20181883T1 (hr) | 2019-01-11 |
EP2994152B1 (fr) | 2018-08-15 |
WO2014180533A3 (fr) | 2015-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2911478C (fr) | Conjugats destines a la protection contre les composes actifs nephrotiqus | |
US10065993B2 (en) | Peptides and peptide/active compound conjugates for renal targeting | |
ES2689147T3 (es) | Conjugados de épsilon-polilisina y uso de los mismos | |
KR102051038B1 (ko) | 나노입자 약물 컨쥬게이트 | |
US20240148721A1 (en) | Discrete peg constructs | |
US20240148916A1 (en) | Bivalent fibroblast activation protein ligands for targeted delivery applications | |
KR102436012B1 (ko) | 항암제 프로드러그 컨쥬게이트의 새로운 용도 | |
US8642555B2 (en) | Prodrugs | |
Luxenhofer | Novel functional poly (2-oxazoline) s as potential carriers for biomedical applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20190412 |
|
EEER | Examination request |
Effective date: 20190412 |
|
EEER | Examination request |
Effective date: 20190412 |
|
EEER | Examination request |
Effective date: 20190412 |
|
EEER | Examination request |
Effective date: 20190412 |